A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Trial Profile

A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Endostatin (Primary) ; Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to completed, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 19 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top